Health groups raise concerns over patents for rare disease drugs

Health groups and patient advocates are raising concerns over patent monopolies on rare disease drugs in India. They argue that these monopolies, like the one held by Roche for the spinal muscular atrophy drug Risdiplam, restrict access to affordable medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i1HIR4y
via IFTTT